Class
DPP-IV Stabilized GHRH Analogue
Molecular Weight
5,135.8 Da
Half-life
26–38 minutes
Purity
≥98% (HPLC)
Form
Lyophilized powder
Storage
Lyophilized: 2–8°C; Reconstituted: 2–8°C
Reconstitution
Sterile water for injection
Mechanism of action
Tesamorelin is a synthetic GHRH analogue with a trans-3-hexenoic acid modification at the N-terminus, which enhances stability against dipeptidyl peptidase IV (DPP-IV) degradation while preserving GHRH receptor binding. It stimulates endogenous GH secretion with preserved physiological pulsatility — a key distinction from exogenous GH administration, which suppresses the HPG axis feedback.
⚠️ For Research Use Only — described exclusively for in vitro and laboratory research by qualified researchers. Not for human or veterinary use. Informational only; does not constitute medical advice or imply efficacy in humans.
Research highlights
~15%
Visceral adipose tissue reduction (HIV-lipodystrophy trial)
FDA
Egrifta — approved for HIV-associated lipodystrophy
Pulsatile
Preserves physiological GH pulse pattern
Cognitive
Emerging data on GH axis and memory in older adults
Research notes
- FDA approval: Tesamorelin (Egrifta) approved for HIV-associated lipodystrophy — significant visceral fat reduction in controlled trials.
- VAT: ~15–18% reduction in visceral fat observed over 26 weeks in clinical research.
- Cognitive: Emerging research on GHRH/GH axis and working memory function in older adults.
- Lipid effects: Improvements in triglycerides and trunk fat distribution observed in multiple studies.
- HPG preservation: Does not suppress the hypothalamic-pituitary-GH axis feedback, unlike exogenous GH.
